Health Care·Life Sciences Tools & Services·$8.4B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.69 | N/A | +0.86% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $1.69 | N/A | +0.86% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed a cautious optimism about future growth driven by strong demand. However, they recognized challenges that could impact performance.
Management highlighted strong demand in key segments.
They acknowledged ongoing challenges in the market environment.
Focus remains on operational efficiency and strategic investments.
Charles River Laboratories reported a positive surprise in EPS, indicating better-than-expected profitability. However, the stock fell by 1.4%, likely due to the lack of revenue data and no guidance provided for future performance. Investors may be concerned about the broader market challenges mentioned by management.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
CONSOLIDATED EDISON
Nov 4, 2019